24340-76-9

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Methylisothiazol-5-amine is used as a synthetic reagent for the creation of pyrrolidinyl ureas, which are potent FPR2 selective agonists. These agonists play a crucial role in the prevention and treatment of heart failure, making 3-methylisothiazol-5-amine an essential component in the development of novel therapeutic strategies for cardiovascular health.

InChI:InChI=1/C4H6N2S/c1-3-2-4(5)7-6-3/h2H,5H2,1H3

Upstream product

• 62069-87-8 β-aminothiocrotonic acid amide 
• 71134-43-5 3-methyl-5-aminoisothiazole hydrochloride 
• 25391-97-3 5-benzoylamino-3-methyl-4-isothiazolecarboxylic acid 
• 22131-51-7 5-amino-3-methyl-1,2-thiazole-4-carboxylic acid 
• 32081-55-3 3-amino-but-2-enethioic acid amide 

Downstream Products

• 52724-43-3 4-acetylamino-N-(3-methyl-isothiazol-5-yl)-benzenesulfonamide 
• 20067-16-7 5-Chlor-3-methyl-isothiazol 
• 57861-24-2 2-(3-methyl-isothiazol-5-ylamino)-benzoic acid 
• 25039-57-0 3-methyl-4-phenylazo-isothiazol-5-ylamine 
• 747357-66-0 2,3-dimethyl-2H-isothiazol-5-ylideneamine 
• 71109-34-7 3-methyl-1,2-thiazolo<5,4-b>pyridine 
• 25039-55-8 4-(3-methyl-isothiazol-5-ylazo)-phenol 
• 693-92-5 3-methylisothiazole 
• 85508-99-2 4-bromo-3-methyl-isothiazol-5-amine 
• 36778-16-2 3-methyl-5-nitroisothiazole 
• 4590-59-4 5-Amino-3-methyl-isothiazol-4-sulfonsaeure 
• 88090-93-1 5-(2-amino-2-methylvinyl)-3-p-chlorophenyl-1,2,4-thiadiazole 
• 71079-27-1 N-cyclohexyl-N'-(3-methyl-isothiazol-5-yl)-N''-(2-methyl-quinolin-4-yl)-guanidine 
• 141859-13-4 5--3-methylisothiazole 

Relevant academic research and scientific papers

Synthesis and experimental versus theoretical research on spectroscopic and electronic properties of 3-methyl-4-nitroisothiazole

The alternative way of synthesis of valuable 5-amino-3-methylisothiazole and 3-methyl-4-nitroisothiazole has been presented and described. It appeared that new, undescribed 3,3′-dimethyl-4,4′-dinitro-5,5′-bisisothiazole has been produced as a side-product during synthesis. Both experimental and calculated spectral and electronic properties of 3-methyl-4-nitroisothiazole have been extensively researched and discussed. The complete vibrational assignments were made on the basis of potential energy distributions PED. The fully anharmonic infrared and Raman spectra with calculated anharmonic intensities for fundamental bands, overtones as well as combination bands are presented. Vibrational spectra predicted by anharmonic approximation agree very well with experimental data. The stability of molecules of 3-methyl-4-nitroisothiazole arising from hyper conjugative interaction has been estimated using natural bond orbital (NBO 6.0) analysis. The combined frontier molecular orbital and NBO analysis of canonical molecular orbitals was used to predict the most probable sites of 3-methyl-4-nitroisothiazole molecule where single electron can be accepted to and detached from. Measured reduction potential of 3-methyl-4-nitroisothiazole and calculated electron affinity point out that this compound is susceptible to reduction at the similar level of 1-methyl-3-nitropyrazole and this susceptibility is much more than respective 1-methyl-4-nitropyrazole. UV-Vis spectra analysis reveals a nature of valence electron excitation and electron transition of 3-methyl-4-nitroisothiazole. Besides, unambiguous assignment of NMR signal shifts of carbon atoms of isothiazole ring of 3-methyl-4-nitroisothiazole, 5-amino-3-methylisothiazole and intermediate and side products of synthesis was conducted thanks to full detailed analysis of 1H, 13C NMR spectra and their two dimensional (2D) variants. Additionally, molar enthalpy of vaporization (ΔHvap) of 3-methyl-4-nitroisothiazole has been estimated (ΔHvap = 52.2 kJ/mol).

Methods for inhibiting protein kinases

The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim-1 kinase, and tyrosine kinase using imidazo[1,2-a]pyrazine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.

Imidazopyrazines as protein kinase inhibitors

In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.

GAMMA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, W, X, and n are defined herein, which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.